Anatomy/
Physiology
Pathophysiology
Pharm
Management
Complications
100

Proinsulin is cleaved into mature insulin and ___________ by proteases in secretory granules.

C-peptide 

100

T1DM involves which immune system (innate or acquired)? 

Both innate and acquired immune system (direct T-cell attack and auto-antibodies).

100

This medication takes longer to become effective because it works at the level of transcription.

Thiazolidinediones (PPAR-gamma)

100

Neutral protamine hagedorn (NPH) is a __________ (rapid/short/intermediate/long)-acting insulin 

Intermediate (peak at 4-10 hours)

100

Diabetic complications are mostly due to __________ (pathophysiologic process).

Nonenzymatic glycation (production of advanced glycation end products)

200

This insulin-dependent glucose transporter is found in the striated muscle and adipose tissue.

GLUT-4 

200

 This type of breathing is found in DKA but NOT HHS

Kussmaul breathing (rapid deep breathing to blow off acid). 

200

Your patient wants to start Semaglutide. You tell her _______ is a severe adverse effect of this drug.

Pancreatitis

200

Two insulins useful for the management of Type 1 diabetes (one for baseline control, and one for post-prandial control) 

Insulin glargine (long-acting) and insulin lispro (rapid-acting) 

200

Increased lipolysis in diabetes can cause these two clinical findings _________________.

Eruptive xanthomatosis, lipemia retinalis

300

What two haplotypes are associated with 90% of T1 diabetes, compared to 40% of the general population?

HLA-DR3 and HLA-DR4

300

Ketogenesis produces ____ and _____ in DKA. 

Acetoacetate and beta-hydroxybutyric acid

300

This class of antidiabetic drugs is renoprotective.

SGLT-2 inhibitors: 

inhibits SGLT-2 inhibitors → increased Na delivery to macula densa → decreased renin production & hyperfiltration

300

What are the cutoff levels for random blood glucose, fasting blood glucose, and HbA1c for diabetes diagnosis? 

-Random blood glucose ≥200 mg/dL (1x for symptomatic pts, or 2x consecutively for asymptomatic pts)

-Fasting plasma glucose ≥126 mg/dL 

-HbA1c ≥ 6.5%

300

The first step of HHS management is administration of ______________ (2 things).

IV normal saline and IV insulin.

400

When insulin binds to its receptor, _________________ is activated and auto-phosphorylates the β-subunits of the receptor.

Tyrosine kinase 

400

A major complication of HHS is dehydration, which can be seen clinically by _____________________ (symptoms). 

Decreased JVP, orthostasis (postural hypotension / postural tachycardia), increased resting HR; skin tenting, dry mucous membranes.

400

These 2 diabetic medications may not be helpful in patients with metabolic syndrome due to their effects on weight.

Thiazolidinediones, sulfonylureas (weight gain)

400

Check HbA1c at least ____ times per year for patients meeting treatment goals, and at least _______ for patients not meeting goals. 

  • 2x/year for patients meeting goals (every 6 months) 

  • 4x/year for patients not meeting goals (every 3 months) 

400

Increased levels of _______ lead to demyelination of peripheral nerves.

Sorbitol (causes osmosis leading to glove and stocking polyneuropathy).

500

The equation for corrected serum Na is _______.

Serum Na = [1.65 x (glucose - 100)] / 100 + measured Na

500
  • The autoantibodies in T1DM are __________.

Anti-glutamic acid decarboxylase antibodies (GAD). 

500

Metformin acts increases insulin sensitivity in these 3 ways:

(1) Inhibits mGPD → inhibit hepatic gluconeogenesis. 

(2) Activates AMPK → decrease gluconeogenesis. 

(3) Increases glycolysis and increases peripheral glucose uptake.

500

Physical exercise is encouraged for type 2 diabetics because it causes ________________ in peripheral target tissues, reducing blood glucose and increasing insulin sensitivity 

Increased GLUT-4 receptor expression

500

The 3 primary electrolyte abnormalities seen in refeeding syndrome are: 

Decreased serum PO4 (primary bioindicator), K+, and Mg 

These predispose to arrhythmias, tetany, CNS symptoms, and rhabdomyolysis 

M
e
n
u